Core Viewpoint - Replimune Group, Inc. is facing a securities fraud lawsuit following significant stock price declines due to regulatory setbacks and alleged misleading statements regarding its clinical trials [1][3]. Group 1: Stock Performance and Regulatory Issues - Replimune's stock plummeted over 70% on July 22 after receiving a Complete Response Letter (CRL) from the FDA, which rejected its application for an advanced melanoma therapy due to insufficient clinical evidence from a Phase 2 study [2]. - The stock experienced another decline of over 40% on September 18 after a Type A meeting with the FDA, leaving the path forward under the accelerated approval pathway uncertain [2]. Group 2: Legal Actions and Investor Eligibility - A complaint has been filed against Replimune, alleging that the company made materially false and misleading statements about its IGNYTE clinical trial and the prospects for regulatory approval of its treatment [3]. - Investors who purchased Replimune common stock between November 22, 2024, and July 21, 2025, and have experienced losses may be eligible to participate in the lawsuit [4]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is September 22, 2025, and a class has not yet been certified [5]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have lost money on their investment [5]. Group 4: Whistleblower Information - Individuals with non-public information about Replimune are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - PubMatic, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its business operations and a significant reduction in ad spend from a top demand-side platform (DSP) partner, which negatively impacted its stock price [2][3]. Group 1: Company Financial Performance - On August 11, 2025, PubMatic released its Q2 2025 financial report, revealing a reduction in ad spend from one of its top DSP partners [2]. - The stock price of PubMatic fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025, following the financial report [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that during the Class Period, PubMatic's executives made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include the failure to disclose the shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [3]. Group 3: Legal Actions - Investors who purchased PubMatic securities during the Class Period can file a lead plaintiff motion by October 20, 2025, to participate in the class action lawsuit [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 29, 2025 [1]. Group 1: Class Action Details - Investors who bought Petco securities between January 14, 2021, and June 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 29, 2025 deadline [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related business model and the strength of its product strategy [5]. - It is claimed that the defendants downplayed the severity of issues affecting Petco's business and overstated its ability to achieve sustainable growth, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vestis Corporation due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's growth potential and business performance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $75,000 in Vestis between May 2, 2024, and May 6, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against Vestis, with a deadline of August 8, 2025, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Financial Performance and Stock Impact - On May 7, 2025, Vestis announced disappointing financial results for Q2 2025, withdrawing its revenue and growth guidance for the full fiscal year and providing lower-than-expected guidance for Q3 2025 [5]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating challenges in customer retention and growth [5]. - Following the announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 11, 2025 [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities between September 17, 2024, and May 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding the effectiveness and safety of RP-A501, which was overstated [5]. - Specific claims include that RP-A501 was less effective than represented, and that changes to its clinical trial protocol increased the risk of Serious Adverse Events [5].

Core Viewpoint - The Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025, for those who bought shares between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Reckitt ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 4, 2025 deadline [2][4]. - The lawsuit alleges that Reckitt failed to warn investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. Group 2: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price following the withdrawal of 2025 guidance [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Centene between December 12, 2024, and June 30, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6]. Group 2: Company Performance and Stock Impact - Centene's stock price fell dramatically from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [5]. - The company announced a reduction in its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75, following a disappointing analysis of its market growth [4]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Iovance Biotherapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, and highlights the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Iovance securities between May 9, 2024, and May 8, 2025, may be eligible to join a class action lawsuit [1][2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which resulted in higher costs and lower revenue due to patient drop-offs and delays in treatment initiation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may not have the necessary experience or resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019, and has been recognized for its success in securities class action settlements [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and cost trends related to Medicaid redetermination processes during the specified Class Period [1][4][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, Indiana, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Lawsuit Details - The lawsuit claims that Elevance misled investors by stating they were effectively monitoring cost trends and that premium rates negotiated with states were sufficient to cover rising Medicaid expenses [4]. - It is alleged that the company did not adequately reflect the impact of Medicaid redeterminations, which resulted in a higher utilization of Medicaid members who remained eligible, as those removed were generally healthier [5]. Investor Information - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].